Lymphomas
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)
- Details
ClinicalTrials.gov ID:
NCT06191744
Diagnosis Type:
NA
USOR Number:
- Address
,
P: